FrancophonIA/ELRC3.0 huggingface dataset:
English: The activity of Viraferon is expressed in terms of IU, with 1 mg of recombinant interferon alfa-2b protein corresponding to 2.6 x l0
Maltese: L-attività ta' Viraferon hija mfissra f'termini ta' IU, u 1 mg ta' proteina ta' interferon alfa-2b rikombinanti li tikkorrispondi għal 2.6 x l0
English: N=503 C95-132/I95-143
Maltese: I N=503 C95-132/I95-143
English: Pure red cell aplasia, idiopathic thrombocytopenic purpura, thrombotic thrombocytopenic purpura
Maltese: Aplasja taċ-ċelluli ħomor puri, purpura tromboċitopenika idjopatika, purpura trombotika tromboċitopenika
English: Recombinant interferon alfa-2b is a water-soluble protein with a molecular weight of approximately 19,300 daltons.
Maltese: L-interferon alfa-2b rikombinanti huwa proteina li tinħall fl-ilma u għandu piż molekulari ta' madwar 19,300 dalton.
English: Ribavirin 15 mg/kg/day as 2 divided doses
Maltese: Ribavirin 15 mg/kg/jum bħala 2 dożi
English: Very rarely:
Maltese: Rari ħafna:
English: Chronic Hepatitis B: Treatment of adult patients with chronic hepatitis B associated with evidence of hepatitis B viral replication (presence of HBV-DNA and HBeAg), elevated alanine aminotransferase (ALT) and histologically proven active liver inflammation and/or fibrosis.
Maltese: It-trattament ta' pazjenti adulti li għandhom l-epatite B kronika assoċjata ma' evidenza ta' replikazzjoni virali ta' l-epatite B (preżenza ta' HBV-DNA u HBeAg), alanine aminotransferase (ALT) elevat u infjammazzjoni u/jew fibrożi attiva fil-fwied li tkun konfermata b'mod istoloġiku.
English: Superior efficacy has been demonstrated with the combination of pegylated interferon with ribavirin (sustained response rate of 61 % achieved in a study performed in naïve patients with a ribavirin dose > 10.6 mg/kg, p < 0.01).
Maltese: Effikaċja superjuri ntweriet bil-kombinazzjoni ta' interferon pegilat ma' ribavirin (rata ta' rispons sostnut ta' 61 % nkisbet fi studju li sar b'pazjenti naïve b'doża ta' ribavirin > 10.6 mg/kg, p < 0.01).
English: If VKH syndrome is suspected, antiviral treatment should be withdrawn and corticosteroid therapy discussed (see section 4.8).
Maltese: Jekk ikun hemm suspett li hemm is-sindrome VKH, il-kura kontra l-virus għandha titwaqqaf u tiġi diskussa terapija b'kortikosterojdi (ara sezzjoni 4.8).
English: Recombinant interferon alfa-2b has exhibited antiproliferative effects in studies employing both animal and human cell culture systems as well as human tumour xenografts in animals.
Maltese: L-interferon alfa-2b rikombinanti wera effetti antiproliferattivi fi studji fejn intużaw kemm sistemi ta' kultura ta' ċelluli umani u ta' l-annimali kif ukoll xenografts ta' tumur uman fl-annimali.
English: Study 2 (P02080) was a randomized, single centre study that enrolled 95 previously untreated adult patients with chronic hepatitis C who were co-infected with HIV.
Maltese: Studju 2 (P02080) kien studju randomised, f'ċentru wieħed li ingaġġa 95 pazjent adult li ma kienux ingħataw kura minn qabel b'epatite Ċ kronika li kienu ko-infettati b'HIV.
English: Pack of 1, 6 or 12.
Maltese: Pakkett b'1, 6 jew 12.
English: pain
Maltese: Sentejn
English: Within the organ system classes, adverse reactions are listed under headings of frequency using the following categories: very common (≥1/10); common (≥1/100, <1/10); rarely (≥1/10,000, <1/1,000); very rarely (<1/10,000); not known.
Maltese: Fost il-klassijiet tassistemi ta' l-organi, ir-reazzjonijiet avversi huma elenkati taħt it-titli tal-frekwenza skond il-kategoriji li ġejjin: komuni ħafna (≥1/10); komuni (≥1/100, <1/10); rari (≥1/10,000, <1/1,000); rari ħafna (<1/10,000); mhux magħruf.
English: 3), severe neutropaenia (< 750/mm 3) or severe discontinued in case of severe leukopaenia (< 1,200/mm thrombocytopaenia (< 70,000/mm3).
Maltese: 3), ta' newtropenja severa (< 750/mm 3) jew ta' jitwaqqaf f'każijiet ta' lewkopenja severa (< 1,200/mm tromboċitopenija severa (< 70,000/mm
English: a: p value based on Cochran-Mantel Haenszel Chi square test. b: p value based on chi-square test. c: subjects < 75 kg received 100 µg/week pegylated interferon alfa-2b and subjects ≥ 75 kg received 150 µg/week pegylated interferon alfa-2b.
Maltese: TIW = tlett darbiet fil-ġmgħa. a: valur p bażat fuq test Cochran-Mantel Haenszel Chi square. b: valur p bażat fuq it-test chi-square. c: individwi < 75 kg irċievew 100 µg/ġimgħa interferon alfa-2b pegilat u individwi ≥ 75 kg irċevew 150 µg/week interferon alfa-2b pegilat. d: dożi ta' ribavirin kien 800 mg għal pazjenti < 60 kg, 1,000 mg għal pazjenti 60-75 kg, u 1,200 mg għal pazjenti > 75 kg.
English: NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER SP Europe, 73, rue de Stalle, B-1180 Bruxelles, Belgium
Maltese: SP Europe, 73, rue de Stalle, B-1180
English: Leukopaenia
Maltese: Lewkopenja
English: Viraferon is available in two different pack sizes:
Maltese: Viraferon jiġi f'sitt daqsijiet ta' pakketti differenti:
English: Cardiac arrhythmias (primarily supraventricular) usually respond to conventional therapy but may require discontinuation of Viraferon therapy.
Maltese: Arritmi kardijaċi (primarjament sopraventrikulari) ġeneralment jirrispondu għat-terapija konvenzjonali iżda jistgħu jeħtieġu t-twaqqif tat-terapija ta' Viraferon.
English: Cap scale
Maltese: Skala talkappa
English: Palpitation, tachycardia Cardiomyopathy
Maltese: Palpitazzjoni, takikardija Kardjomijopatija
English: Caution should be used when adding Viraferon and ribavirin to HAART therapy (see ribavirin SPC).
Maltese: Għandha tintuża attenzjoni meta jiżdiedu Viraferon u ribavirin mat-terapija HAART (ara l-SPC ta' ribavirin).
English: Musculoskeletal and connective tissue disorders Very common:
Maltese: Disturbi muskolu-skeletali u tal-connective tissue Komuni ħafna:
English: Pharyngitis*, infection viral* Bronchitis, sinusitis, herpes simplex (resistance), rhinitis Pneumonia§
Maltese: Farinġite*, infezzjoni virali* Bronkite, sinusite, herpes simplex (reżistenza), flissjoni Pnewmonja§
English: In these patients, the addition of ribavirin to Viraferon increased by as much as 10-fold the efficacy of Viraferon used alone in the treatment of chronic hepatitis C (48.6 % vs. 4.7 %).
Maltese: F'dawn il-pazjenti, meta ribavirin ingħata ma' Viraferon żied b' 10 darbiet l-effettività ta' Viraferon użat waħdu fit-trattament ta' lepatite Ċ kronika (48.6 % vs. 4.7 %).
English: Female: amenorrhea, menorrhagia, menstrual disorder, vaginal disorder
Maltese: Mara: amenorreja, menorraġja, disturbi mestrwali, disturbi filvaġina
English: multidose pen 18 million IU/pen
Maltese: INDIVIDWALI 18-il miljun IU/pinna
English: In general, the adverse event profile in the limited paediatric population studied was similar to that observed in adults, although there is a paediatric specific concern regarding growth inhibition as decrease in height (mean percentile decrease of growth velocity of 9 %) and weight (mean percentile decrease of 13 %) percentile were observed during treatment (see section 4.4).
Maltese: B'mod ġenerali, il-profil ta' każijiet avversi fil-popolazzjoni pedjatrika limitata kien jixbah lill-dak ta' l-adulti, għalkemm hemm tħassib speċifiku għat-tfal dwar l-inibizzjoni tat-tkabbir bħal tnaqqis fit-tul (perċentwali medja ta' tnaqqis fir-rata ta' tkabbir b'9%) u fil-piż (perċentwali medja ta' tnaqqis ta' 13 %) perċentwali dehret waqt il-kura (ara sezzjoni 4.4).
English: Table 2 Adverse reactions very commonly and commonly reported in paediatric clinical trials Very common (≥1/10) - Common (≥1/100, <1/10)
Maltese: Tabella 2 Reazzjonijiet avversi irrapurtati b'mod komuni ħafna u komuni fil-provi kliniċi pedjatriċi Komuni ħafna (≥1/10) - Komuni (≥1/100, <1/10) Klassi tas-sistema ta' lorgani
English: In clinical trials using Viraferon therapy, 2.8 % patients overall developed thyroid abnormalities.
Maltese: Fi provi kliniċi bl-użu tatterapija b'Viraferon, 2.8 % tal-pazjenti kollha żviluppaw anormalitajiet tat-tirojde.
English: Amenorrhea, breast pain, dysmenorrhea, menorrhagia, menstrual disorder, vaginal disorder
Maltese: Amenorreja, uġigħ fis-sider, dismenorreja, menorraġja, disturbi mestrwali, disturbi fil-vaġina
English: 10 vials of powder, 10 ampoules of solvent, 10 injection syringes, 20 injection needles and 10 cleansing swabs
Maltese: 10 kunjetti ta' trab, 10 ampulli ta' solvent, 10 siringi għall-injezzjoni, 20 labra għall-injezzjoni u 10 tajjar għat-tindif.
English: Insert the needle into the pinched skin at an angle of 45° to 90°.
Maltese: Daħħal illabra f'angolu ta' bejn 45° u 90° fil-ġilda maqrusa 'l barra.
English: Rubber membrane
Maltese: Membrana tal-gomma
English: België/Belgique/Belgien Rue de Stalle/Stallestraat 73
Maltese: Rue de Stalle/Stallestraat 73
English: 2 Laguno M, Murillas J, Blanco J.L et al. AIDS 2004; 18(13): F27-F36.
Maltese: 2 Laguno M, Murillas J, Blanco J.L et al.
English: Reproductive system and breast disorders Common:
Maltese: Disturbi fis-sistema riproduttiva u fisKomuni:
English: STATEMENT OF ACTIVE SUBSTANCE(S)
Maltese: MANIFATTUR TAS-SUSTANZA BIJOLOĠIKA ATTIVA
English: Tel: + 39-02 21018.1
Maltese: Segrate (Milano) Tel: + 39-02 21018.1
English: Neoplasm (unspecified)
Maltese: Neoplażmi (mhux speċifikati)
English: Children and adolescents - Chronic Hepatitis C
Maltese: Tfal u adolexxenti - Epatite Ċ Kronika
English: §, rash maculopapular, rash erythematous, eczema, erythema, skin disorder Stevens Johnson syndrome, toxic epidermal necrolysis, erythema multiforme
Maltese: §, raxx makulopapulari, raxx bi ħmura, ekżema, ħmura, disturbi tal-ġilda Sindrome Stevens Johnson, nekroliżi tossika tal-ġilda, erythema multiforme
English: Table 3 Sustained virologic response rates with Viraferon + ribavirin (one year of treatment) by genotype and viral load
Maltese: Tabella 3 Rati ta' rispons viroloġiku sostnut b'Viraferon + ribavirin (sena waħda ta' trattament) skond il-ġenotip u l-viral load
English: Diagram A
Maltese: Disinn A
English: Viraferon alone:
Maltese: Viraferon waħdu:
English: Pack sizes of 1.
Maltese: Pakketti ta' daqsijiet b'1.
English: Sustained virological response based on genotype after Viraferon in combination with ribavirin versus pegylated interferon alfa-2b in combination with ribavirin in HCV/HIV co-infected patients
Maltese: Tabella 4 Rispons viroloġiku sostnut ibbażat fuq il-ġenotip wara Viraferon flimkien ma' ribavirin kontra interferon alfa-2b pegilat flimkien ma' ribavirin f'pazjenti ko-infettati b'HCV/HIV
English: MIU = million international units; TIW = three times a week.
Maltese: MIU = miljun unit internazzjonali;
English: Diagram Q
Maltese: Disinn Q
English: Arthralgia, myalgia, musculoskeletal pain
Maltese: Artralġja, mijalġja, uġigħ muskolskeletali
English: Treatment should be blood cells < 1,500/mm
Maltese: It-trattament għandu demm < 1,500/mm
English: Using a sterilised injection syringe and injection needle, inject 1 ml water for injections into the vial of Viraferon.
Maltese: Permezz ta' siringa u labra għall-injezzjoni sterilizzati, injetta 1 ml ta' ilma għall-injezzjonijiet ġolkunjett ta' Viraferon.
English: Chronic hepatitis B:
Maltese: Epatite B Kronika:
English: Suicide, suicide attempts, aggressive behaviour (sometimes directed against others), psychosis including hallucinations
Maltese: Suwiċidju, attentati ta'suwiċidju, imġieba aggressiva (kulltant indirizzata lejn l-oħrajn), psikożi inklużi alluċinazzjonijiet
English: Acute hypersensitivity reactions (e.g., urticaria, angioedema, bronchoconstriction, anaphylaxis) to interferon alfa-2b have been observed rarely during Viraferon therapy.
Maltese: Reazzjonijiet ta' sensittività eċċessiva akuta (eż. urtikarja, anġjoedima, bronkokostrizzjoni, anafilassi) għall-interferon alfa-2b dehru f'każijiet rari waqt it-terapija b'Viraferon.
English: Nervous system disorders§ Very common:
Maltese: Disturbi fis-sistema nervuża Komuni ħafna:
English: Cases of Vogt-Koyanagi-Harada (VKH) syndrome have been reported in patients with chronic hepatitis C treated with interferon.
Maltese: Każijiet tas-sindrome Vogt-Koyanagi-Harada (VKH) kienu rrappurtati f'pazjenti b'epatite Ċ kronika kkurati b'interferon.
English: For paediatric patients who weigh < 47 kg or cannot swallow capsules, see ribavirin oral solution SPC).
Maltese: Għal pazjenti pedjatriċi li jiżnu < 47 kg jew li ma jistgħux jibilaw kapsuli, ara l-SPC tas-soluzzjoni orali ribavirin).
English: Pack sizes of 1, 2 or 12
Maltese: Pakketti ta' daqsijiet b'1, 2 jew 12
English: Diagram D
Maltese: Disinn D
English: A wide variety of autoimmune and immune-mediated disorders have been reported with alpha interferons including thyroid disorders, systemic lupus erythematosus, rheumatoid arthritis (new or aggravated), idiopathic and thrombotic thrombocytopenic purpura, vasculitis, neuropathies including mononeuropathies (see also section 4.4).
Maltese: Varjetà kbira ta' problemi awtoimmunitarji u ta' problemi konnessi ma' l-immunità kienu irrappurtati bl-interferoni alpha, u jinkludu disturbi tat-tirojde, lupus erythematosus sistemika, artrite rewmatika (tibda jew taggrava), purpura idjopatika u tromboċitopenika trombotika, vaskulite, u newropatiji li jinkludu mononewropatiji (ara wkoll sezzjoni 4.4).
English: Collect necessary items before you begin: a vial of Viraferon powder for injection; an ampoule of solvent for Viraferon (water for injections 1 ml); a 2 ml syringe; a long needle (for example 0.8 × 40 mm [21 gauge 1.5 inch]) to be used to add water for injections to the Viraferon powder vial; a short needle (for example 0.3 × 13 mm [30 gauge 0.5 inch]) for the subcutaneous injection; a cleansing swab.
Maltese: Iġbor l-oġġetti li se jkollok bżonn qabel tibda: kunjett ta' Viraferon, trab għall-injezzjoni; ampulla ta' solvent għal Viraferon (ilma għall-injezzjonijiet 1 ml); siringa ta' 2 ml; labra twila (per eżempju 0.8 × 40 mm [21 gauge 1.5 pulzieri]) biex iżżid l-ilma għallinjezzjonijiet ġol-kunjett tat-trab ta' Viraferon; labra qasira (per eżempju 0.3 × 13 mm [30 gauge 0.5 pulzieri]) għall-injezzjoni taħt il-ġilda; tajjara għat-tindif.
English: N=505 C95-132/I95-143
Maltese: I/R N=505 C95-132/I95-143
English: Detailed information on this medicine is available on the European Medicines Agency (EMEA) web site: http://www.emea.europa.eu/
Maltese: Informazzjoni dettaljata dwar din il-mediċina tinsab fuq il-website ta' l-Aġenzija Ewropeja dwar ilMediċini (EMEA) http://www.emea.europa.eu/.
English: Pharyngitis*, infection viral* Bronchitis, sinusitis, herpes simplex (resistance), rhinitis Pneumonia
Maltese: Farinġite*, infezzjoni virali* Bronkite, sinusite, herpes simplex (reżistenza), flissjoni Pnewmonja
English: Sarcoidosis, exacerbation of sarcoidosis Systemic lupus erythematosus, vasculitis, rheumatoid arthritis (new or aggravated), Vogt-Koyanagi-Harada syndrome, acute hypersensitivity reactions including urticaria, angioedema, bronchoconstriction, anaphylaxis
Maltese: Sarkojdożi, tiħrax s-sarkojdożi Lupus erythematosus sistemika, vaskulite, artrite rewmatika (tibda jew taggrava), sindrome Vogt-Koyanagi-Harada, reazzjonijiet ta' sensittività eċċessiva akuti li jinkludu urtikarja, anġjoedema, bronkokostrizzjoni, anafilassi
English: Depression, emotional lability, insomnia Suicidal ideation, aggressive reaction, confusion, behaviour disorder, agitation, somnambulism, anxiety, nervousness, sleep disorder, abnormal dreaming, apathy
Maltese: Depressjoni, burdati emozzjonali, nuqqas ta' rqad Ħsiebijiet dwar suwiċidju, reazzjoni aggressiva, konfużjoni, disturbi fl-imġieba, aġitazzjoni, ħmar il-lejl, ansjetà, nervi, disturbi fl-irqad, ħolm anormali, apatija
English: Infection and infestations Very common:
Maltese: Infezzjonijiet u infestazzjonijiet Komuni ħafna:
English: Psychiatric and central nervous system (CNS): Severe CNS effects, particularly depression, suicidal ideation and attempted suicide have been observed in some patients during Viraferon therapy, and even after treatment discontinuation mainly during the 6-month follow-up periodand in the follow-up period.
Maltese: Psikjatrika u sistema nervuża ċentrali (CNS): Effetti severi tas-CNS, l-aktar dipressjoni, ħsibijiet ta' suwiċidju u attentati ta' suwiċidju dehru f'xi pazjenti waqt terapija b'Viraferon, u anki wara li twaqqfet il-kura waqt is-6 xhur fil-perijodu ta' follow-up.
English: Interferon alfa-2b (6 MIU/m2 3 times a week for 6 months) has been given to children with chronic active hepatitis B. Because of a methodological flaw, efficacy could not be demonstrated.
Maltese: Interferon alfa-2b (6 MIU/m² tlett darbiet fil-ġimgħa għal 6 xhur) ingħata lil tfal b'epatite B attiva kronika.
English: CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 18 million IU/3 ml
Maltese: INDIVIDWALI 18-il miljun IU/3 ml
English: The administered dose should be reduced by 50 % in case of occurrence of haematological disorders (white blood cells < 1,500/mm3, granulocytes < 1,000/mm3, thrombocytes < 100,000/mm3).
Maltese: Id-doża mogħtija għanda titnaqqas b'50 % f'każ li jseħħu problemi ematoloġiċi (ċelluli bojod taddemm < 1,500/mm3, granuloċiti < 1,000/mm3, tromboċiti < 100,000/mm3).
English: CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 10 million IU/1 ml
Maltese: INDIVIDWALI 10 miljun IU/1 ml
English: Thyroid dysfunction during treatment with interferon alfa-2b and ribavirin has been observed.
Maltese: Dehret funzjoni ħażina tat-tirojde waqt il-kura b'interferon alfa-2b u ribavirin.
English: Mean (% CV) multiple-dose pharmacokinetic parameters for Viraferon and ribavirin capsules when administered to children or adolescents with chronic hepatitis C Parameter
Maltese: Medja (% CV) tal-parametri farmakokinetiċi b'ħafna dożi għal Viraferon u kapsuli ribavirin meta jingħataw lil tfal jew adolexxenti b'epatite Ċ kronika Parametru
English: (See ribavirin capsule SPC for dose of ribavirin capsules and dosage modification guidelines for combination therapy.
Maltese: (Ara l-SPC tal-kapsuli ribavirin u l-linji gwida għal tibdil fid-dożaġġ għal terapija kombinata.
English: There are no reports of virus transmissions with albumin manufactured to European Pharmacopoeia specifications by established processes.
Maltese: M'hemmx rapporti ta' tixrid ta' virus b'albumina manifatturata skond speċifikazzjonijiet tal-European Pharmacopoeia bi proċessi stabbiliti.
English: CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 25 million IU/2.5 ml
Maltese: INDIVIDWALI 25 miljun IU/2.5 ml
English: Anaemia, neutropaenia Thrombocytopaenia, lymphadenopathy
Maltese: Anemija, newtropenja Tromboċitopenja, limfadenopatija
English: Diagram R
Maltese: Disinn R
English: Diagram M
Maltese: Disinn M
English: EXP
Maltese: Kappa
English: Diagram G
Maltese: Disinn G
English: If you have them, you may have had a serious allergic reaction to Viraferon.
Maltese: Jekk ikollok minnhom, jista' jkun li kellek reazzjoni allerġika serja għal Viraferon.
English: Viraferon has been classified as recombinant interferon alfa-2b.
Maltese: Viraferon kienet ikklassifikata bħala interferon alfa-2b rikombinanti.
English: Commonly reported side effects (at least 1 in every 100 patients, but less than 1 in every 10 patients): thirst, dehydration, high blood pressure, migraines, swollen glands, flushing, menstrual problems, decreased sexual drive, vaginal problem, breast pain, pain in testicle, problems with thyroid gland, red gums, dry mouth, red or sore mouth or tongue, tooth ache or tooth disorder, herpes simplex (fever blisters), taste change, upset stomach, dyspepsia (heartburn), constipation, enlargement of liver (liver problems, sometimes severe), loose stools, bedwetting in children, inflammation of the sinuses, bronchitis, eye pain, problem with your tear ducts, conjunctivitis (“pink eye”), agitation, sleepiness, sleepwalking, problem with behaviour, nervousness, stuffy or runny nose, sneezing, rapid breathing, pale or reddened skin, bruising, fingers and toes very sensitive to cold, problem with skin or nails, psoriasis (new or worsened), increased sweating, increased need to pass urine, fine shaking movements, decreased sensitivity to touch, arthritis.
Maltese: Effetti sekondarji rrappurtati b'mod komuni (mill-anqas 1 f'kull 100 pazjent, iżda anqas minn 1 f'kull 10 pazjenti): għatx, deidratazzjoni, pressjoni għolja, attakki tal-migranja, glandoli minfuħin, fwawar, problemi mestrwali, tnaqqis fix-xewqa sesswali, prblemi fil-vaġina, uġigħ tas-sider, uġigħ fit-testikoli, problemi bil-glandola tat-tirojde, ħanek jiħmar, ħalq xott, il-ħalq jew l-ilsien jiħmaru jew jinstelħu, uġigħ fissnien jew disturbi fis-snien, herpes simplex (nuffati tad-deni), tibdil fit-togħma, taqlib ta' l-istonku, dispepsja (ħruq ta' stonku), stitikezza, tkabbir tal-fwied (problemi bil-fwied, kultant severi), ippurgar maħlul, tixrib tas-sodda fit-tfal, infjammazzjoni tas-sinus, bronkite, uġigħ fl-għajnejn, problema bittubi tad-dmugħ, konġunktivite (“għajn roża”), aġitazzjoni, ngħas, ħmar il-lejl, problema bl-imġieba, nervi, imnieħer imblukkat jew inixxi, għatis, nifs imgħaġġel, ġilda pallida jew ħamra, tbenġil, swaba ta' l-idejn u tar-riġlejn isiru sensittivi ħafna għal kesħa, problema bil-ġilda jew id-dwiefer, prorajiżi (tibda jew tmur għall-agħar), żieda fl-għaraq, żieda fil-bżonn li tgħaddi l-awrina, movimenti ta' tregħid żgħir, nuqqas ta' sensittività biex tħoss, artrite.
English: Nausea/vomiting, abdominal pain, diarrhoea, stomatitis, dyspepsia
Maltese: Tqalligħ/rimettar, uġigħ fl-addome, dijarea, stomatite, dispepsja
English: Patients were randomized to receive either pegylated interferon alfa-2b (100 or 150 µg /week based on weight) plus ribavirin (800-1,200 mg/day based on weight) or Viraferon (3 MIU TIW) plus ribavirin (800-1,200 mg/day based on weight).
Maltese: Il-pazjenti kienu randomised sabiex jirċievu interferon alfa-2b pegilat (100 or 150 µg /ġimgħa skond il-piż) flimkien ma' ribavirin (800-1,200 mg/jum skond il-piż) jew Viraferon (3 MIU TIW) flimkien ma' ribavirin (800 mg-1,200 mg/jum skond il-piż).
English: Diagram J
Maltese: Disinn J
English: Treatment should be blood cells < 1,500/mm discontinued in case of severe leukopaenia (< 1,200/mm 3), severe neutropaenia (< 750/mm 3) or severe thrombocytopaenia (< 70,000/mm
Maltese: It-trattament għandu demm < 1,500/mm jitwaqqaf f'każijiet ta' lewkopenja severa (< 1,200/mm3), ta' newtropenja severa (< 750/mm3) jew ta' tromboċitopenija severa (< 70,000/mm3).
English: More than 14 genetically distinct human alpha interferons have been identified.
Maltese: Kienu identifikati aktar minn 14-il interferon alpha umani ġenetikament distinti.
English: Raynaud's disease, flushing, pallor
Maltese: Marda ta' Raynaud, fwawar, pallidità
English: Interferon alfa-2b has been shown to have abortifacient effects in Macaca mulatta (rhesus monkeys) at 90 and 180 times the recommended intramuscular or subcutaneous dose of 2 million IU/m Abortion was observed in all dose groups (7.5 million, 15 million and 30 million IU/kg), and was statistically significant versus control at the mid- and high-dose groups (corresponding to 90 and 180 times the recommended intramuscular or subcutaneous dose of 2 million IU/m2).
Maltese: L-abort kien innutat fil-kategoriji tad-dożi kollha (7.5 miljuni, 15-il miljun u 30 miljun IU/kg) u kien statistikament sinifikattiv meta mqabbel mal-kontroll fil-kategoriji tad-doża l-medja u ta' dik għolja (li tikkkorrispondi għal 90 u 180 darba iktar mid-doża rakkomandata ta' 2 miljun IU/m² ġol-muskolu jew taħt il-ġilda).
English: Male: testicular pain
Maltese: Raġel: uġigħ fit-testikoli
English: During treatment for hepatitis B or C the recommended testing schedule is at weeks 1, 2, 4, 8, 12, 16, and every other month, thereafter, throughout treatment.
Maltese: Matul it-trattament għall-epatite B jew Ċ, l-iskeda rrakkomandata għat-testijiet hija fil-ġimgħat numru 1, 2, 4, 8, 12, 16, u wara dan kull xahrejn tul iż-żmien kollu tat-trattament.
English: + ribavirin
Maltese: Il-Belġju
English: Chronic hepatitis B: 5 to 10 million IU 3 times a week (every other day) injected subcutaneously (under the skin).
Maltese: Epatite B kronika: 5 sa 10 miljun IU 3 darbiet fil-ġimgħa (darba kull jumejn) injettati taħt il-ġilda.
English: Viraferon is a sterile, stable, formulation of highly purified interferon alfa-2b produced by recombinant DNA techniques.
Maltese: Viraferon huwa formulazzjoni sterili u stabbli ta' interferon alfa-2b ippurifikat sa grad għoli ħafna magħmul bit-teknika tad-DNA rikombinanti.